5-bromo-2-[(6-fluoropyridin-2-yl)oxy]phenol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-bromo-2-[(6-fluoropyridin-2-yl)oxy]phenol
• 英文别名: 5-Bromo-2-(6-fluoropyridin-2-yl)oxyphenol
• 化学式: C₁₁H₇BrFNO₂
• 分子量: 284.084
• InChiKey: YEEIGTZLSBLGBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-二氟吡啶 在 三溴化硼 、 potassium hydroxide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.0h， 生成 5-bromo-2-[(6-fluoropyridin-2-yl)oxy]phenol
  参考文献：
  名称：

  From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria

  摘要：

  In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from. its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically, relevant Gram negative bacteria that is currently undergoing clinical trails.

  DOI：

  10.1021/jm301113w

文献信息

• Hydroxyphenyl derivatives and biological applications thereof
  申请人：Mutabilis SA

  公开号：EP1845087A1

  公开（公告）日：2007-10-17

  The invention relates to hydroxyphenyl derivatives of formula (I) and the pharmaceutically acceptable salts, the organic and mineral salts, the racemic and each non racemic derivatives, the cis (Z) and Lrans (E) isomers the tautomers. Application particularly as anti-bacterial and/or anti-parasite agents.

  该发明涉及公式(I)的羟基苯基衍生物及其药用可接受的盐，有机和矿物盐，外消旋和每种非外消旋衍生物，顺式（Z）和反式（E）异构体，互变异构体。特别用作抗菌和/或抗寄生虫剂。
• From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria
  作者：Vincent Gerusz、Alexis Denis、Fabien Faivre、Yannick Bonvin、Mayalen Oxoby、Sophia Briet、Géraldine LeFralliec、Chrystelle Oliveira、Nicolas Desroy、Cédric Raymond、Laëtitia Peltier、François Moreau、Sonia Escaich、Vanida Vongsouthi、Stéphanie Floquet、Elodie Drocourt、Armelle Walton、Laure Prouvensier、Marc Saccomani、Lionel Durant、Jean-Marie Genevard、Vanessa Sam-Sambo、Coralie Soulama-Mouze

  DOI：10.1021/jm301113w

  日期：2012.11.26

  In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from. its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically, relevant Gram negative bacteria that is currently undergoing clinical trails.